

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS & FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA
UNSTARRED QUESTION NO. 3531
TO BE ANSWERED ON THE 8TH August 2017

Upgradation of NIPER, Chandigarh

3531. SHRIMATI ANJU BALA:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether the Government has received suggestions regarding improvement/upgradation of the National Institute of Pharmaceutical Education and Research (NIPER), Chandigarh from the Parliamentary Delegation which visited the institute recently in June 2017 and if so, the details thereof;

(b) the number of patents granted to NIPER during the last decade (2007-2017) and its major achievements during the said period;

(c) whether the Government is planning to upgrade the very old machinery installed in NIPER which is now in redundant condition and if so, the details thereof; and

(d) the steps taken/being taken and funds allocated by the Government for development of NIPER as Model Pharmaceutical Research Organisation during the last three years?

ANSWER

**MINISTER OF STATE IN THE MINISTRY OF ROAD TRANSPORT AND HIGHWAYS;
MINISTRY OF SHIPPING AND MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI
MANSUKH L. MANDAVIYA)**

(a) No madam. The Parliamentary Standing Committee on Chemicals & Fertilizers has undertaken a study visit to NIPER, Mohali in June, 2017 in connection with examination of various subjects selected by the Committee. Subsequently, an Oral Evidence before the Standing Committee on the subject "Promotion and Co-ordination of Basic Applied Research in areas related to Pharmaceutical Sector" with a special reference to budgetary allocation to NIPERs for R&D activities was held on 30.06.2017 at Parliament House, New Delhi. However, recommendations/suggestions of the Committee on the subject have not been received as yet.

(b) NIPER, Mohali has filed 112 Patents, out of which 40 Patents have been granted during the period 2007-2017. The major achievements of the Institute during the period are indicated in the Annexure.

(c) Standing Finance Committee (SFC) of the Department in its meeting held on 25.8.2015 has approved an amount of Rs. 249.455 crore under the teaching and infrastructure components for NIPER, Mohali. An amount of Rs. 9.79 crore was released to NIPER, Mohali during Financial Year 2015-16 for up-gradation.

(d) Grants of Rs. 88.05 crore have been released to NIPER, Mohali during the last three years (2014-15 to 2016-17) under plan and non-plan heads.

1. Institutional recognition:

- 1.1 Ranked second best pharmacy Institute in the country in the National Institutional *Ranking* Framework (*NIRF*), 2017 of Ministry of Human Resource Development, Government of India.
- 1.2 Received Thomson Reuters Innovation Award, 2011 (Govt. sector).

2. Research output:

- 2.1 Publications: >2000
- 2.2 Patents granted: 41 (including international)
- 2.3 National and international awards to faculty members, including Shanti Swaroop Bhatnagar Award, National Bioscience Award, Ranbaxy Research Award, J. C. Bose Fellowship, etc.
- 2.4 National and international fellowships of academic societies, including Indian National Science Academy, Indian Pharmacological Society, National Academy of Sciences, American Association of Pharmaceutical Sciences, etc.
- 2.5 National and international awards to students, including Sun Pharma/ Ranbaxy research scholar award, Commonwealth fellowship, DAAD fellowship, Nehru-Fulbright fellowship, Lindau Nobel Laureates' Meet, etc. In addition, students were awarded by many national and international agencies as well as international pharmaceutical companies to attend and present their research work in seminars/conferences (>100 during the period).

3. Support to industry:

- 3.1 Establishment of:
 - (i) National Toxicology Centre, the first GLP-certified set-up for toxicology testing in the government sector;
 - (ii) Small and Medium Pharmaceutical Industry Centre, which makes available the Institute's facilities to SMEs at half the cost and also provides didactic and hands-on training in regulatory and analytical training for these entities.
- 3.2 Technologies transferred: Three (Four are in the pipeline)
- 3.3 Seven MoUs signed with industries to promote industry-academia partnership, including those with Sun Pharma, Biocon, Wockhardt, Panacea Biotec, etc.
- 3.4 Consultancies provided to the industry

4. Placement of students:

- 4.1 Students placed in top pharma companies (domestic and multi-nationals).
